α2β1

Integrin α2β1 functions as a principal collagen-binding receptor that mediates cell-extracellular matrix (ECM) adhesion, mechanosensing, and intracellular signaling^[1]. Mechanistically, α2β1 engagement activates downstream kinases including p38α, Src family kinases, PLCγ2, and PI3Kβ, thereby regulating cytoskeletal rearrangements, platelet spreading, and smooth muscle cell migration^[2][3][4][5]. Compared with related isoforms, such as α1β1, α2β1 specifically upregulates type I collagen transcription via its α2 cytoplasmic tail and selectively activates signaling pathways including Cdc42-MKK3/4, whereas α1β1 preferentially triggers Shc-Ras/ERK signaling^[2]. In disease contexts, α2β1 contributes to metastatic processes in breast carcinoma and melanoma by promoting proliferation, invasion, and anoikis resistance, as well as modulating tumor-ECM interactions and immune evasion^[6][1][7]. In platelet biology, α2β1 mediates outside-in signaling independent of GPVI-FcRγ complex, coordinating tyrosine phosphorylation and calcium mobilization essential for thrombus formation^[4][5]. Agonists such as the thrombospondin-1-derived peptide 4N1K enhance α2β1-dependent chemotaxis via Gi-mediated suppression of ERK activity and cAMP levels^[3]. Small-molecule inhibitors targeting the I-like domain of the β1 subunit, including CSW4-161, effectively block collagen adhesion and platelet aggregation with high specificity and low toxicity, demonstrating utility for anti-thrombotic applications^[8]. Additionally, biologically derived inhibitors, including snake venom C-type lectin proteins and Kunitz-type molecules like Bannakunin, selectively antagonize α2β1-mediated platelet functions while sparing other integrins^[9][10].